Printer Friendly

MICROPROBE RESPONDS TO GEN-PROBE'S PATENT INFRINGEMENT SUIT

 BOTHELL, Wash., May 18 /PRNewswire/ -- MicroProbe Corporation, based here, today announced that it received a complaint for patent infringement of Gen-Probe Inc.'s U.S. Patent No. 4,851,330. Gen-Probe, a wholly owned subsidiary of the Japanese company, Chugai Pharmaceutical Co. Ltd., claims that MicroProbe is infringing the patent and requests an injunction against MicroProbe.
 According to John Bishop, MicroProbe's chairman and chief executive officer, the company has evaluated the Gen-Probe patent in light of prior art, and believes that the claims are invalid. In addition, MicroProbe's Affirm(TM) VP Identification System provides a significant cost-effective alternative to the diagnosis of a medical condition that results in more than 10 million physician office visits each year.
 "Gen-Probe request for injunction is difficult to understand, particularly since none of our products infringe the patent in question," said Bishop. "There is no alternative diagnostic product on the market today that offers the benefits of MicroProbe's Affirm VP System. We believe that Gen-Probe would be unsuccessful in any injunctive action."
 Through its diagnostic division, MicroProbe is the first company to bring the benefits of DNA probe technology directly to the physician's office. The company makes diagnostic systems for the rapid and simultaneous identification of infectious disease organisms from a single patient sample. Currently sold in the United States, the company's Affirm(TM) VP System detects the presence of Trichomonas vaginalis and Gardnerella vaginalis, organisms associated with vaginitis.
 The first in a family of tests, the Affirm(TM) VP System was introduced in October 1992 to advance women's health care with gynecological and obstretic benefits. According to MicroProbe, the initial market response for the product has been very positive and enthusiastic because the product offers a more sensitive, accurate and objective result than any other method currently available.
 MicroProbe has a strong patent portfolio behind its technology, including 14 issued patents through its diagnostics and therapeutics divisions. The company is developing practical applications of oligonucleotides for the diagnosis and treatment of infectious disease, utilizing proven principles of biochemical control.
 In addition to producing DNA probe-based systems for the rapid identification of infectious-disease microorganisms, MicroProbe is involved in research aimed at the discovery and development of new classes of therapeutics that selectively block genes and disease-causing proteins of chronic viral infections and certain cancers.
 -0- 5/18/93 R
 /CONTACT: Greg Sessler, chief financial officer of MicroProbe, 206-485-8566, or Charles Versaggi, Gable-Versaggi Biocommunications, 408-358-4162/


CO: MicroProbe Corporation, Gen-Probe ST: Washington IN: HEA SU:

443 05-18-93 08:04 EDT 23:46 -- NY013R -- 9739 05/18/93 11:55 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 18, 1993
Words:424
Previous Article:SUMMIT ANNOUNCES OPENING OF NEW IMAGE LASER CENTERS
Next Article:ZDS INTRODUCES NEW MEMBERS OF Z-SERVER FAMILY, PLUS PENTIUM PROCESSOR UPGRADES
Topics:


Related Articles
GEN-PROBE FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. FOR PATENT INFRINGEMENT
MICROPROBE AGREES GEN-PROBE PATENTS VALID
MICROPROBE SIGNS BINDING AGREEMENT TO SELL DIAGNOSTICS BUSINESS
Gen-Probe granted summary judgment in Enzo patent lawsuit.
Gen-Probe settles patent dispute with Vysis, acquires license for amplified products.
IRIDEX Files Suit Against Synergetics USA, Inc.
Appeals court affirms summary judgment in favor of Gen-Probe in Enzo patent lawsuit.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters